Argatroban is an anticoagulant that is a direct thrombin inhibitor. Argatroban was approved in 2000 for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia (HIT). Argatroban is a direct thrombin inhibitor that reversibly binds to the thrombin active site. Argatroban exerts its anticoagulant effects by inhibiting thrombin-catalyzed or -induced reactions, including fibrin formation; activation of coagulation factors V, VIII, and XIII; activation of protein C; and platelet aggregation. Argatroban inhibits thrombin with an inhibition constant (Ki) of 0.04 μM.
Libralon, Giovanna; Nicole, Andrea; Zanon, Jacopo. Method for the preparation of argatroban monohydrate. Assignee Lundbeck Pharmaceuticals Italy S.p.A.. 2008.
Kikumoto, Ryoji. Method for the preparation of N2-arylsulfonyl-NG-nitro-L-arginines and their piperidinamide derivatives. Assignee Mitsubishi Chemical Corp. 1998.
Liu, Jian; Li, Hongling; Ma, Yaping; Yuan, Jiancheng. Method for synthesizing argatroban through combination of solid-phase synthesis and liquid-phase synthesis. Assignee Shenzhen Hanyu Pharmaceutical Co., Ltd. Hybio Pharmaceutical Co., Ltd. 2009.
